Guidelines for the management of castrate-resistant prostate cancer.
about
The emerging role of histone lysine demethylases in prostate cancerMechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesNovel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsReal-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cellsLow-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer.Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect ComparisonIntravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapyManagement of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice.Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CTChemotherapy for prostate cancer: Clinical practice in Canada.Optimal management of patients receiving cabazitaxel-based chemotherapyMetastatic castration-resistant prostate cancer: The emerging continuum of care.Emerging novel therapies in the treatment of castrate-resistant prostate cancer.Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.Statin derivatives as therapeutic agents for castration-resistant prostate cancer.CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer.Acetonitrile extract of Salvia miltiorrhiza Radix exhibits growth-inhibitory effects on prostate cancer cells through the induction of cell cycle arrest and apoptosisMedication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel.Oxibendazole inhibits prostate cancer cell growth.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.
P2860
Q21245762-381EC0F2-65C5-4FEC-ACFB-19154D336549Q26774221-070F3767-D5A5-4A88-81D5-5342D2422282Q26795445-33F8E554-C003-47AA-A5AB-0A5B1897D2EAQ26796704-018B3281-EAAD-4F28-8967-8C0DCB3F3A18Q28545928-6D46C76C-781B-4B6D-BA98-5258B9F732FDQ33652859-1AD0985D-A8E7-46CD-9AB2-4AF5FFD6E226Q33904772-EE31FB08-95D4-434B-BAFA-A2615172D6A3Q34115708-C848D61B-D0CA-4C40-A764-1319F6A374A0Q34278259-0349B065-7476-4B6C-A4DC-E94541D26590Q34412589-3F030458-ECB6-4D26-9D8A-636B04A2483EQ35742655-1C70ED9A-8F40-40A9-AC12-648A57E10498Q36387830-B24FC121-A6D1-4EB7-A487-6CEF759659E3Q36478792-86BF2358-2093-4B05-A7F3-09916A1C1705Q36507013-2B41C15B-E024-4E86-8BCD-8614080DFEE7Q36838375-379578AA-496C-4CF7-8DD3-77158E74EDDEQ36838378-392888C7-CC0A-4FB7-A519-C1DF8662F338Q36838381-D204C239-27A1-41DE-8A44-BD210BE96E8AQ37862392-C57A26A0-B156-4059-A2E1-29D85A813B15Q38194528-6889431F-B5C7-4EF6-8D6A-F35D4C3BEA70Q38375972-D066FB6D-44B7-43AE-9F61-8B254810F19CQ38704252-E3FFA5B4-DB0A-4B11-96C4-936783B1CF73Q38735989-6AF25337-92A0-4AB6-86CE-DAA6E7B9FDECQ38931938-EE5FE7BB-9006-4445-9C41-659947E8B10FQ42267744-CA93B31B-7C82-47DE-95BF-0E27D0E063C1Q42366791-F6D33D00-8C7A-4438-96D8-09C6F7004030Q43225374-9839A4FC-14B5-4C78-BBE8-4D89D057B048Q49530055-C4D761CA-E519-4FF7-903D-3F9BB0F6D1EFQ53735518-4AE10807-1C80-4FA1-B39D-C6F0F6DBECAAQ55158890-6AACFC98-4918-4EDD-9C6D-5A81D871EB8E
P2860
Guidelines for the management of castrate-resistant prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Guidelines for the management of castrate-resistant prostate cancer.
@ast
Guidelines for the management of castrate-resistant prostate cancer.
@en
Guidelines for the management of castrate-resistant prostate cancer.
@nl
type
label
Guidelines for the management of castrate-resistant prostate cancer.
@ast
Guidelines for the management of castrate-resistant prostate cancer.
@en
Guidelines for the management of castrate-resistant prostate cancer.
@nl
prefLabel
Guidelines for the management of castrate-resistant prostate cancer.
@ast
Guidelines for the management of castrate-resistant prostate cancer.
@en
Guidelines for the management of castrate-resistant prostate cancer.
@nl
P2860
P356
P1476
Guidelines for the management of castrate-resistant prostate cancer.
@en
P2093
Sebastien J Hotte
P2860
P304
P356
10.5489/CUAJ.10167
P577
2010-12-01T00:00:00Z